Sun Pharma Q4 Results Review - Stepping Up Specialty Investments In FY25: Prabhudas Lilladher

Prabhudas Lilladher Report

Our FY25/FY26 earnings estimates stands marginally reduced by 2% as we factor in higher research and development spend. Sun Pharmaceutical Industries Ltd. Q4 FY24 Ebitda was in line with our estimate, aided by domestic formulation and specialty sales.

Overall specialty sales, gross margins continue to remain healthy. Over last few years Sun Pharma dependency on U.S. generics has reduced and company’s growth is more functional on specialty, rest of world and domestic pharma business that has strong growth visibility.

Though FY25 expenses may remain elevated given company are in investment phase to ramp up specialty pipeline; launch of deuruxolitinib along with progress of other pipelines provides visibility to Sun Pharma’s specialty pipeline beyond FY25.

We maintain ‘Buy’ rating at target price of Rs 1710 based on 32 times FY26E earnings. Sun Pharma remains our top pick in large cap space.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.